You are here
P&T January 2019 ePub
Influenza activity during the 2017–2018 season was high, with an estimated 48.8 million people becoming ill, 959,000 hospitalizations and 79,400 deaths. Xofulza (baloxavir marboxil) is a new antiviral agent approved by the FDA on October 24, 2018. This drug forecast article reviews the pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, safety profile, and place in therapy of Xofluza.